Behavioral Patterns of PTCT and Institutional Flows
This article provides an AI-generated analysis of Ptc Therapeutics Inc. (NASDAQ: PTCT), indicating a neutral sentiment in the near term that could moderate mid-term weakness, despite elevated downside risk. It outlines three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for PTCT.
Director Steele Glenn Jr MD PHD Sells 12,000 Shares of PTC Thera
Director Steele Glenn Jr MD PHD sold 12,000 shares of PTC Therapeutics Inc (PTCT), adding to a consistent pattern of insider selling at the company, with 69 insider sells and no buys over the past year. The stock is considered "Significantly Overvalued" by GuruFocus's GF Value, despite some institutional guru accumulation. Investors are advised to monitor future clinical and regulatory milestones and any changes in insider trading patterns.
PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock
PTC Therapeutics (NASDAQ:PTCT) Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the company's stock for $781,920.00, reducing his holdings by 34.78%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, the company recently exceeded Q2 earnings expectations, and analysts generally maintain a "Moderate Buy" rating with an average price target of $99.08.
After exercising options at $11.23, a director sold 12,000 PTC Therapeutics (PTCT) shares at $65.16.
PTC Therapeutics director Glenn Jr. MD, PhD Steele exercised 12,000 options at $11.23 per share and subsequently sold all 12,000 common shares at $65.16 per share on September 30, 2026. These transactions, which generated an approximate pre-tax spread of $647,000, were conducted under a Rule 10b5-1 plan adopted in March 2026. The options were currently exercisable and had an expiration date of January 2, 2027.
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares.
PTC Therapeutics director Glenn D. Steele Jr. has proposed selling 12,000 common shares worth $781,920.00, which were acquired through a stock option exercise. The sale is scheduled for September 30, 2026, with Fidelity Brokerage Services LLC acting as the broker. This transaction is detailed in a Form 144 SEC filing.
Non-controlling/minority interest of PTC Therapeutics, Inc. – HAN:BH3
This article provides financial information regarding the non-controlling/minority interest of PTC Therapeutics, Inc., traded under the ticker BH3 on the Hannover Stock Exchange. It notes that the market was closed and no trades occurred, indicating a focus on financial data rather than real-time stock performance. The content is primarily a data page from TradingView, referencing information from ICE Data Services, FactSet, and Quartr.
PTC Therapeutics Jumps 5.5% Amid Sector-Wide Rally
PTC Therapeutics (PTCT) saw its stock jump 5.5% on Monday, closing at $66.13, as part of a broad sector-wide rally in biotechnology stocks. The gain was attributed to overall investor momentum and a shift in risk appetite towards biotech, rather than any company-specific news or developments. Other sector peers like GRAL and TVTX also experienced similar gains, suggesting a collective movement within the industry.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics has announced inducement grants of stock options and restricted stock units (RSUs) to 11 new employees. These grants, totaling 161,250 stock options and 32,800 RSUs, were made outside of the company's stockholder-approved equity incentive plan. The grants were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4).
37 new hires get options to buy PTC shares at $65.96
PTC Therapeutics (PTCT) approved stock options and restricted stock units for 37 new employees on September 22, 2026. The grants include options to purchase 51,270 common shares at an exercise price of $65.96 per share and 37,995 restricted stock units. These inducement awards, made under Nasdaq Listing Rule 5635(c)(4), vest over four years, subject to the employees' continued service with the company.
PTC Therapeutics (PTCT) Stock Looks Expensive As Its 175% Run Draws Focus
PTC Therapeutics (PTCT) has seen a 175% stock increase over the past three years, prompting questions about its current valuation relative to sales. Despite a P/S ratio of 5.2x, which is below the biotech industry average, Simply Wall St's Fair Ratio model suggests the stock is overvalued based on its fundamentals, including growth, margins, size, and risk. The company's acquisition of the ST-920 Fabry disease gene therapy program and future commercial delivery are key factors that could potentially justify a higher multiple.
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com
PTC Therapeutics has completed its acquisition of ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics, Inc. The company plans to submit a rolling Biologics License Application to the FDA for accelerated approval of ST-920 in the fourth quarter of 2026. ST-920 is a one-time administered AAV gene therapy that has received multiple designations from the FDA and European Medicines Agency, and is designed to address the limitations of chronic enzyme replacement therapy for Fabry disease.
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026
PTC Therapeutics has completed the acquisition of ST-920, a gene therapy for Fabry disease, from Sangamo. The company anticipates completing a rolling Biologics License Application (BLA) submission for accelerated FDA approval in the fourth quarter of 2026. This BLA is supported by positive Phase 1/2 STAAR data showing significant renal benefits and a favorable safety profile.
PTC Therapeutics completes ST-920 gene therapy acquisition
PTC Therapeutics has finalized its acquisition of ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics, Inc. The company plans to submit a Biologics License Application to the FDA for accelerated approval of ST-920 in the fourth quarter of 2026. ST-920, known as isaralgagene civaparvovec, is designed as a one-time treatment and has received several expedited designations from regulatory agencies.
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026.
PTC Therapeutics has completed its acquisition of ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics. A rolling Biologics License Application (BLA) submission to the FDA for accelerated approval is anticipated to be completed in Q4 2026. ST-920 is a one-time administered AAV gene therapy that has shown promise in clinical studies for long-term enzyme production and reduction of disease markers.
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00
Cantor Fitzgerald increased its price target for PTC Therapeutics (NASDAQ:PTCT) to $137.00 from $130.00, maintaining an "overweight" rating and suggesting a nearly 110% upside. The biopharmaceutical company has a "Moderate Buy" consensus rating among analysts, with an average price target of $99.08, despite its shares trading near their 52-week low. PTC Therapeutics recently surpassed quarterly expectations with $0.92 EPS and $360.52 million in revenue, a 101.5% year-over-year increase.
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com
PTC Therapeutics has completed its acquisition of ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics. The company plans to submit a Biologics License Application to the FDA for accelerated approval of ST-920 in the fourth quarter of 2026. ST-920 is a one-time administered AAV gene therapy that has received multiple designations for its potential to treat Fabry disease by addressing the underlying enzyme deficiency.
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PTC Therapeutics, Inc. has announced the completion of its acquisition of ST-920, a BLA-stage, one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc. The company expects to complete the rolling Biologics License Application (BLA) submission to the FDA for accelerated approval in Q4 2026. ST-920 (isaralgagene civaparvovec) has received Orphan Drug, Fast Track, and RMAT designations from the FDA, along with similar designations from European and UK regulatory bodies, and aims to provide a durable treatment option for Fabry disease patients.
PTC Therapeutics Closes Acquisition of the ST-920 Gene Therapy for Fabry Disease
PTC Therapeutics has completed its acquisition of ST-920, a gene therapy aimed at treating Fabry Disease. The article, however, appears to be a premium content piece, requiring a subscription to read the full details.
PTC Therapeutics (NASDAQ: PTCT) director offloads 20,000 shares under trading plan
PTC Therapeutics director Michael Schmertzler, through Section Six Partners, L.P., sold 20,000 shares of PTCT common stock on September 16–17, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan at weighted-average prices between $65.99 and $68.84 per share. Schmertzler retains a direct holding of 163,266 shares of PTCT.
Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT
Bank of America Corp DE has acquired a new position of 1.45 million shares, valued at $118.46 million, in PTC Therapeutics during the second quarter, representing 1.74% of the company. This comes as several other institutional investors also initiated positions, while company insiders sold approximately $15.1 million of stock in the last 90 days. PTC Therapeutics reported strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" consensus with an average price target of $98.50.
Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy"
Wall Street Zen has upgraded PTC Therapeutics (NASDAQ:PTCT) to a "strong-buy" rating, despite a broader analyst consensus of "Moderate Buy" and a target price of $98.50. This upgrade follows stronger-than-expected quarterly results, with EPS of $0.92 against a $0.24 consensus and revenue up 101.5% year-over-year. However, the stock opened below its 50-day and 200-day moving averages, and insiders have sold approximately $15.1 million worth of stock in the last 90 days.
PTC Therapeutics (NASDAQ:PTCT) Director Sells 10,000 Shares
Michael Schmertzler, a director at PTC Therapeutics (NASDAQ:PTCT), sold 10,000 shares of the company's stock for $671,200. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings to 1,306,594 shares. The transaction follows several other sales by Schmertzler in recent months, while the company's shares recently dropped 3.9% despite reporting stronger-than-expected earnings and revenue.
PTC Therapeutics Director Michael Schmertzler Executes 20,000 Share Sale Under 10b5-1 Trading Plan
Michael Schmertzler, a director at PTC Therapeutics, Inc. (NASDAQ:PTCT), sold a total of 20,000 shares of the company's common stock on September 16 and 17, 2026. These transactions were carried out through Section Six Partners, L.P. under a pre-established Rule 10b5-1 trading plan adopted on May 14, 2026. Following these sales, Schmertzler indirectly holds 1,296,594 shares and directly holds 163,266 shares, while disclaiming beneficial ownership of shares held by Section Six Partners, L.P. except for his pecuniary interest.
PTC Therapeutics at Morgan Stanley conference: sephience drives outlook By Investing.com
PTC Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its transition into a diversified rare disease company driven by the success of its new PKU therapy, Sephience. The company raised its full-year 2026 revenue guidance to $850 million to $950 million and remains on track for cash flow breakeven, despite facing pressure in its older Duchenne muscular dystrophy franchise. PTC also discussed its pipeline, including vatiquinone for Friedreich’s ataxia, votoplam for Huntington’s disease, and the recent acquisition of ST-920 for Fabry disease, outlining several near-term clinical and regulatory milestones.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages
PTC Therapeutics (NASDAQ:PTCT) has received a "Moderate Buy" recommendation from brokerages, with an average 12-month price target of $98.50, significantly higher than its current price of $66.48. The company recently exceeded quarterly earnings expectations, reporting $0.92 adjusted EPS and $360.52 million in revenue, a 101.5% year-over-year increase. Despite strong performance, company insiders, including the CEO and a VP, have sold shares totaling approximately $16.8 million over the last three months under Rule 10b5-1 plans.
California State Teachers Retirement System Lowers Holdings in PTC Therapeutics, Inc. $PTCT
The California State Teachers Retirement System reduced its stake in PTC Therapeutics by 3.1% in Q2 2026, selling 2,587 shares and retaining 81,733 shares worth $6.7 million. Despite this reduction, analyst sentiment remains positive with a "Moderate Buy" rating and a target price of $98.50. PTC Therapeutics reported strong Q2 earnings, beating EPS and revenue estimates, with quarterly revenue up 101.5% year-over-year.
Leerink Partners Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)
Leerink Partners has initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with an "outperform" rating and a $98 price target, suggesting a 46.73% upside. This aligns with the "Moderate Buy" consensus and average target of $98.50 from other analysts. PTC Therapeutics recently surpassed EPS and revenue estimates, though insider selling has occurred alongside new institutional investments.
PTC Therapeutics at Wells Fargo conference: sufiance drives growth plan By Investing.com
PTC Therapeutics outlined its strategy at the Wells Fargo 21st Annual Healthcare Conference, focusing on transitioning to a broader rare disease portfolio driven by its SUFIANCE product. The company aims for cash flow breakeven in 2026 and expects SUFIANCE to generate over $2 billion in revenue, having surpassed initial launch expectations. PTC also discussed its pipeline, including programs for Huntington's disease, Friedreich's ataxia, and an acquisition of a Fabry gene therapy asset, alongside managing the decline of legacy products like Translarna.
Corient Private Wealth LP Makes New Investment in PTC Therapeutics, Inc. $PTCT
Corient Private Wealth LP has made a new investment in PTC Therapeutics, Inc. (NASDAQ:PTCT), purchasing 15,115 shares valued at approximately $1.23 million in the second quarter. The article notes that several other institutional investors also bought or increased their positions, while company insiders sold shares worth about $17.7 million. PTC Therapeutics exceeded its quarterly earnings and revenue expectations, and analysts currently hold a "Moderate Buy" consensus with an average price target significantly above the current share price.
Sangamo Therapeutics (OTC: SGMOQ) to Sell ST-920 Asset to PTC Therapeutics for $111M Plus Milestones
Sangamo Therapeutics has agreed to sell its ST-920 asset, an AAV gene therapy candidate for Fabry disease, to PTC Therapeutics for $111 million in cash, plus up to $100 million in potential milestone payments. These milestone payments are contingent upon accelerated and full FDA approvals. The transaction is pending approval from the Bankruptcy Court, with a hearing scheduled for September 10, 2026.
Hsbc Holdings PLC Takes $10.76 Million Position in PTC Therapeutics, Inc. $PTCT
HSBC Holdings PLC has acquired a new stake of 131,389 shares in PTC Therapeutics, Inc. valued at approximately $10.76 million. This investment comes amidst increased institutional activity in PTCT, with several other funds also adjusting their positions. Despite some insider selling under pre-arranged plans, analysts maintain a "Moderate Buy" rating for PTC Therapeutics, which recently exceeded its quarterly earnings and revenue estimates.
PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments >PTCT
This article announces that PTC Therapeutics will receive an upfront payment of $111 million, with the potential for an additional $100 million in contingent milestone payments. This significant financial influx is expected to support the company's ongoing research and development efforts.
Palo Alto Investors LP Invests $74.95 Million in PTC Therapeutics, Inc. $PTCT
Palo Alto Investors LP has made PTC Therapeutics, Inc. (NASDAQ:PTCT) its largest portfolio position by acquiring 918,846 shares valued at approximately $74.95 million. Despite insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $98.55, following PTC Therapeutics' strong quarterly revenue and EPS beat. The biopharmaceutical company focuses on therapies for rare genetic disorders and reported a 101.5% year-over-year revenue increase.
Ptc Therapeutics Announces New Sephience Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as Well as Consistent Favorable Safety Profile
PTC Therapeutics announced new scientific data for Sephience (sepiapterin) will be presented at the 2026 SSIEM Annual Symposium. The data highlights Sephience's benefits for individuals with phenylketonuria (PKU), showing sustained metabolic control, significant diet liberalization, and a consistent favorable safety profile, including for those with classical PKU and high baseline Phe levels. Sephience, a natural precursor of BH4, is approved in multiple regions and effectively reduces blood phenylalanine levels across a broad range of PKU patients.
PTCT Looks 84.3% Overvalued on GF Value™
PTC Therapeutics (
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
PTC Therapeutics announced new data on Sephience (sepiapterin) for phenylketonuria (PKU), to be presented at the SSIEM Symposium. The data reinforces Sephience's benefits in lowering phenylalanine, enabling diet liberalization, and maintaining metabolic control across all PKU patient subgroups, including those with classical PKU, with a consistent favorable safety profile. Analyses from the AMPLIPHY study and real-world data show significant improvements in blood Phe levels and dietary freedom for patients.
Price to earnings forward of PTC Therapeutics, Inc. – NASDAQ:PTCT
This article provides a financial data point for PTC Therapeutics, Inc. (NASDAQ: PTCT), specifically its forward price-to-earnings ratio. The content itself is very minimal, presenting only the company name, stock ticker, and the financial metric without any further details or analysis. The page appears to be a stub or a data point from a larger financial platform.
PTC Therapeutics director Schmertzler disposes of $1.8m in stock
Michael Schmertzler, a director at PTC Therapeutics, Inc. (NASDAQ:PTCT), recently sold approximately $1.8 million worth of common stock in mid-August through several transactions. These sales, conducted under a Rule 10b5-1 trading plan, occurred between August 19 and August 20, 2026, with share prices ranging from $70.78 to $73.67. This comes as analysts predict profitability for the company this year, with recent strong Q2 2026 results surpassing expectations.
PTC Therapeutics director Schmertzler disposes of $1.8m in stock By Investing.com
Michael Schmertzler, a director at PTC Therapeutics Inc. (NASDAQ: PTCT), recently sold common stock worth approximately $1.8 million through several transactions in mid-August 2026. The sales were executed under a Rule 10b5-1 trading plan. Despite the company not being profitable in the last twelve months, analysts predict profitability for the current year, with recent strong Q2 2026 results surpassing expectations.
PTC Therapeutics (NASDAQ: PTCT) director sells 25,000 shares in 10b5-1 trade
Michael Schmertzler, a director at PTC Therapeutics (PTCT), indirectly sold 25,000 shares of common stock between August 19-20, 2026, through Section Six Partners, L.P. The sales were executed under a Rule 10b5-1 plan adopted on May 14, 2026, with weighted average prices ranging from the low $70s to mid $73s per share. Schmertzler retains direct ownership of 163,266 shares of PTCT common stock.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $98.55, significantly higher than its recent trading price of $70.52. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue up 101.5% year-over-year. Despite recent stock declines and insider selling, several institutional investors have increased their stakes in PTC Therapeutics.
PTC Therapeutics (PTCT) Shares Moved, What Is Behind The Attention Today?
PTC Therapeutics (PTCT) is gaining attention due to an expected completion of the ST-920 approval process in Q4 2026, supported by positive Phase 1/2 data. Despite recent short-term share price dips, its long-term performance remains strong, and analysts view the stock as undervalued, forecasting a fair value of $96.93 against its current $70.52. However, risks include reliance on a few products and ongoing losses that might necessitate further funding.
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920
PTC Therapeutics recently discussed the positive regulatory progress of ST-920, supported by Phase 1/2 STAAR data showing significant renal benefits and a favorable safety profile. This development could reshape the company's investment narrative and pipeline, diversifying beyond its current commercial base. While PTC Therapeutics raised its 2026 revenue guidance, the success of ST-920 and other gene therapies will be crucial for long-term growth and profitability.
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock
PTC Therapeutics VP Mark Elliott Boulding sold 2,813 shares of the company's stock on August 17th for a total of $204,139.41, reducing his ownership by 2.60%. This sale was part of a pre-arranged Rule 10b5-1 trading plan and follows earlier sales in June and July. The company's stock traded up by $1.04 to $73.67, with a market capitalization of $6.15 billion, and recently beat earnings and revenue estimates.
PTC Therapeutics (NASDAQ: PTCT) holder plans 50,000-share resale
A holder of PTC Therapeutics (NASDAQ: PTCT) plans to resell 50,000 common shares. The shares will be sold by Michael Schmertzler through Section Six Partners, LP, via Merrill Lynch on NASDAQ. These shares were acquired on July 4, 2012, and the sale is being conducted under Rule 144, which outlines conditions for the legal resale of restricted or insider-held shares.
PTC Therapeutics (NASDAQ: PTCT) CLO sells 2,813 shares under 10b5-1 plan
Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics (NASDAQ: PTCT), exercised stock options for 2,813 shares at $25.69 per share and subsequently sold these shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. These transactions were executed under a pre-adopted Rule 10b5-1 plan. Following the sale, Boulding still holds 16,876 stock options from the same grant and 105,272 shares of common stock.
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920
PTC Therapeutics' bull case is potentially shifting due to positive renal data and regulatory progress for its gene therapy, ST-920, highlighted by a recent special call. This development underscores PTC's growing focus on rare disease gene therapies and portfolio diversification beyond its current commercial base. While the immediate future still relies on existing product performance, ST-920's advancement offers a new pillar for the company's long-term investment narrative and financial outlook.
PTC Therapeutics (NASDAQ: PTCT) insider lines up $201,692 share sale
An insider at PTC Therapeutics (NASDAQ: PTCT), Mark Boulding, has filed a Form 144 notice to sell 2,813 shares of common stock valued at $201,692.10. This planned sale is scheduled for August 17, 2026, following a stock option exercise. The filing also revealed previous sales by Boulding, including 10,522 shares on June 17, 2026, and 5,079 shares on July 6, 2026.
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTC Therapeutics plans to acquire the ST-920 Fabry disease gene therapy asset for $111 million in a bankruptcy auction, with potential additional payments of up to $100 million based on U.S. regulatory milestones. This acquisition aims to leverage PTC's existing global commercial and regulatory infrastructure to add a potential one-time treatment for Fabry disease to its rare disease portfolio. The ST-920 program, an AAV gene replacement therapy, is based on promising Phase I/II STAAR study results, showing positive eGFR slope and sustained alpha-galactosidase A activity, and has received multiple FDA designations.
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT
Assenagon Asset Management S.A. significantly reduced its stake in PTC Therapeutics, Inc. by 88.8% in Q2, retaining 6,899 shares valued at $563,000, while other institutions like Segall Bryant & Hamill increased their positions. Despite insider selling worth $15.65 million, PTC Therapeutics reported strong Q2 revenue of $360.52 million, up 101.5% year-over-year, and adjusted EPS of $0.92, significantly beating analyst estimates. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $98.55.
